vs

Side-by-side financial comparison of Bristol Myers Squibb (BMY) and ROYAL BANK OF CANADA (RY). Click either name above to swap in a different company.

ROYAL BANK OF CANADA is the larger business by last-quarter revenue ($13.1B vs $11.5B, roughly 1.1× Bristol Myers Squibb). ROYAL BANK OF CANADA runs the higher net margin — 32.2% vs 23.3%, a 8.9% gap on every dollar of revenue.

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...

The Royal Bank of Canada is a Canadian multinational financial services company and the largest bank in Canada by market capitalization. The bank serves over 18 million clients and has more than 98,000 employees worldwide. Founded in 1864 in Halifax, Nova Scotia, it maintains its corporate headquarters in Toronto and its head office in Montreal. RBC's institution number is 003. In November 2017, RBC was added to the Financial Stability Board's list of global systemically important banks.

BMY vs RY — Head-to-Head

Bigger by revenue
RY
RY
1.1× larger
RY
$13.1B
$11.5B
BMY
Higher net margin
RY
RY
8.9% more per $
RY
32.2%
23.3%
BMY

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BMY
BMY
RY
RY
Revenue
$11.5B
$13.1B
Net Profit
$2.7B
$4.2B
Gross Margin
Operating Margin
Net Margin
23.3%
32.2%
Revenue YoY
11.0%
Net Profit YoY
8.8%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMY
BMY
RY
RY
Q1 26
$11.5B
$13.1B
Q4 25
$12.5B
Q3 25
$12.2B
$12.4B
Q2 25
$12.3B
$11.4B
Q1 25
$11.2B
Q4 24
$12.3B
Q3 24
$11.9B
Q2 24
$12.2B
Net Profit
BMY
BMY
RY
RY
Q1 26
$2.7B
$4.2B
Q4 25
$1.1B
Q3 25
$2.2B
$4.0B
Q2 25
$1.3B
$3.2B
Q1 25
$2.5B
Q4 24
$72.0M
Q3 24
$1.2B
Q2 24
$1.7B
Gross Margin
BMY
BMY
RY
RY
Q1 26
Q4 25
67.2%
Q3 25
71.9%
Q2 25
72.5%
Q1 25
72.9%
Q4 24
61.0%
Q3 24
75.1%
Q2 24
73.2%
Operating Margin
BMY
BMY
RY
RY
Q1 26
Q4 25
11.8%
Q3 25
25.5%
Q2 25
14.5%
Q1 25
26.5%
Q4 24
1.4%
Q3 24
14.1%
Q2 24
10.5%
Net Margin
BMY
BMY
RY
RY
Q1 26
23.3%
32.2%
Q4 25
8.7%
Q3 25
18.0%
31.9%
Q2 25
10.7%
28.0%
Q1 25
21.9%
Q4 24
0.6%
Q3 24
10.2%
Q2 24
13.8%
EPS (diluted)
BMY
BMY
RY
RY
Q1 26
Q4 25
$0.54
Q3 25
$1.08
Q2 25
$0.64
Q1 25
$1.20
Q4 24
$0.05
Q3 24
$0.60
Q2 24
$0.83

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMY
BMY
RY
RY
Cash + ST InvestmentsLiquidity on hand
$9.6B
$33.7B
Total DebtLower is stronger
$-42.2B
Stockholders' EquityBook value
$102.1B
Total Assets
$1709.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMY
BMY
RY
RY
Q1 26
$9.6B
$33.7B
Q4 25
$10.2B
Q3 25
$15.7B
$25.5B
Q2 25
$12.6B
$35.5B
Q1 25
$10.9B
Q4 24
$10.3B
Q3 24
$7.9B
Q2 24
$6.3B
Total Debt
BMY
BMY
RY
RY
Q1 26
$-42.2B
Q4 25
$44.8B
Q3 25
$48.7B
Q2 25
$48.9B
Q1 25
$49.5B
Q4 24
$49.4B
Q3 24
$49.5B
Q2 24
$52.0B
Stockholders' Equity
BMY
BMY
RY
RY
Q1 26
$102.1B
Q4 25
$18.5B
Q3 25
$18.6B
$99.0B
Q2 25
$17.4B
$96.7B
Q1 25
$17.4B
Q4 24
$16.3B
Q3 24
$17.1B
Q2 24
$17.0B
Total Assets
BMY
BMY
RY
RY
Q1 26
$1709.9B
Q4 25
$90.0B
Q3 25
$96.9B
$1626.4B
Q2 25
$94.7B
$1636.8B
Q1 25
$92.4B
Q4 24
$92.6B
Q3 24
$93.7B
Q2 24
$94.6B
Debt / Equity
BMY
BMY
RY
RY
Q1 26
Q4 25
2.43×
Q3 25
2.63×
Q2 25
2.81×
Q1 25
2.85×
Q4 24
3.03×
Q3 24
2.89×
Q2 24
3.05×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMY
BMY
RY
RY
Operating Cash FlowLast quarter
$27.7B
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
6.55×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMY
BMY
RY
RY
Q1 26
$27.7B
Q4 25
$2.0B
Q3 25
$6.3B
$21.2B
Q2 25
$3.9B
$7.2B
Q1 25
$2.0B
Q4 24
$4.4B
Q3 24
$5.6B
Q2 24
$2.3B
Free Cash Flow
BMY
BMY
RY
RY
Q1 26
Q4 25
$1.6B
Q3 25
$6.0B
Q2 25
$3.6B
Q1 25
$1.7B
Q4 24
$4.1B
Q3 24
$5.3B
Q2 24
$2.1B
FCF Margin
BMY
BMY
RY
RY
Q1 26
Q4 25
12.8%
Q3 25
49.0%
Q2 25
29.0%
Q1 25
15.1%
Q4 24
32.9%
Q3 24
44.3%
Q2 24
16.9%
Capex Intensity
BMY
BMY
RY
RY
Q1 26
Q4 25
3.0%
Q3 25
2.6%
Q2 25
2.9%
Q1 25
2.3%
Q4 24
3.1%
Q3 24
2.7%
Q2 24
2.1%
Cash Conversion
BMY
BMY
RY
RY
Q1 26
6.55×
Q4 25
1.82×
Q3 25
2.87×
5.36×
Q2 25
2.99×
2.24×
Q1 25
0.80×
Q4 24
61.65×
Q3 24
4.62×
Q2 24
1.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons